Discover
TARS
Tarsus Pharmaceuticals, Inc.
68.56
1 x 68.48
3 x 68.64
bid
ask
+
0.80
1.18%
01:35 PM
timesize
| Ytd | -16.26% | |
| 1y | 36.93% |
66.34
day range
68.79
48.20
52 week range
85.25
| Open | 67.28 | Prev Close | 67.76 | Low | 66.34 | High | 68.79 | Mkt Cap | 2.95B |
| Vol | 344.44K | Avg Vol | 970.37K | EPS | -1.09 | P/E | -62.96 | Forward P/E | 25.84 |
| Beta | 0.53 | Short Ratio | 4.26 | Inst. Own | 107.56% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 08-06 | 50-d Avg | 61.37 | 200-d Avg | 68.40 | 1yr Est | 94.25 |
| Income Statement | |||
| Total Revenue | 173.91M | ||
| Revenues (USD) | 173.91M | ||
| Cost of Revenue | 12.11M | ||
| Gross Profit | 161.80M | ||
| Operating Expenses | 181.71M | ||
| Research and Development Expense | 31.01M | ||
| Selling, General and Administrative Expense | 150.70M | ||
| Operating Income | -19.91M | ||
| Interest Expense | 2.16M | ||
| Income Tax Expense | 2.72M | ||
| Net Income | -18.55M | ||
| Net Income Common Stock | -18.55M | ||
| Net Income Common Stock (USD) | -18.55M | ||
| Consolidated Income | -18.55M | ||
| Earnings per Basic Share | -0.43 | ||
| Earnings per Basic Share (USD) | -0.43 | ||
| Earnings per Diluted Share | -0.43 | ||
| Earning Before Interest & Taxes (EBIT) | -13.68M | ||
| Earning Before Interest & Taxes (USD) | -13.68M | ||
| Weighted Average Shares | 43.39M | ||
| Weighted Average Shares Diluted | 43.39M | ||
| Balance Sheet | |||
| Cash and Equivalents | 204.60M | ||
| Cash and Equivalents (USD) | 204.60M | ||
| Investments | 253.78M | ||
| Investments Current | 245.10M | ||
| Investments Non-Current | 8.68M | ||
| Trade and Non-Trade Receivables | 98.31M | ||
| Current Assets | 561.99M | ||
| Property, Plant & Equipment Net | 30.40M | ||
| Total Assets | 611.14M | ||
| Total Debt | 72.76M | ||
| Current Liabilities | 175.75M | ||
| Debt Non-Current | 72.76M | ||
| Total Liabilities | 264.41M | ||
| Accumulated Retained Earnings (Deficit) | -452.15M | ||
| Accumulated Other Comprehensive Income | -557.00K | ||
| Shareholders Equity | 346.73M | ||
| Shareholders Equity (USD) | 346.73M | ||
| Assets Non-Current | 49.15M | ||
| Total Debt (USD) | 72.76M | ||
| Goodwill and Intangible Assets | 6.89M | ||
| Inventory | 6.90M | ||
| Liabilities Non-Current | 88.66M | ||
| Trade and Non-Trade Payables | 40.14M | ||
| Cash Flow | |||
| Depreciation, Amortization & Accretion | 1.09M | ||
| Net Cash Flow from Financing | 3.30M | ||
| Net Cash Flow / Change in Cash & Cash Equivalents | 102.40M | ||
| Capital Expenditure | -4.07M | ||
| Issuance (Purchase) of Equity Shares | 3.30M | ||
| Net Cash Flow from Investing | 37.88M | ||
| Net Cash Flow - Investment Acquisitions and Disposals | 41.95M | ||
| Net Cash Flow from Operations | 61.22M | ||
| Share Based Compensation | 13.29M | ||